Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, and bispecifics will bring another shift.
Angie Maynard, PharmD, MS
Advertisement
Articles by Angie Maynard, PharmD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FAQs: FDA Lawsuit Challenges E-Cigarette Enforcement Policy, PMTA Guidance
2
Tec-Dara Closes Survival Gap in High-Risk MM: Rahul Banerjee, MD
3
Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog
4
PMOS Linked to 4-Fold Atherosclerotic Heart Disease Risk in 2.5 Million US Women
5